|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Effect of norethisterone and levonorgestrel in low-dose multiphasic oral |
| contraceptives on serum lipids. |
| Wiik P; Nordby J; Paulsen JE |
| Acta Obstetrica et Gynecologica Scandinavica. 1993 Oct;72(7):550-5. |
| In a parallel, multicenter study in Norway and Finland involving a total of 196 healthy women (mean age 22.4 years, |
| range 18-30), the effects on serum lipids and lipoproteins of two multiphasic oral contraceptives (OCs) containing |
| ethinyl estradiol (EE) but different progestins were examined. One formulation contained EE 35 mcg and |
| norethisterone (NET) 0.5 mg on days 1-7 and days 17-21 and elevated NET 1.0 mg during the midphase (days 8-16). |
| The other formulation contained EE 30 mcg on days 1-6 and days 12-21 and 40 mcg on days 7-11 and phased |
| levonorgestrel (LGN): 50 mcg (days 1-6), 75 mcg (days 7-11) and 125 mcg (days 12-21). Both formulations induced |
| significant elevation of total cholesterol (6.7 and 4.1%), Apo B (8.1 and 7.0%) as well as HDL (6.4 and 3.7%) for the |
| EE/NET and EE/LGN formulation respectively. Mean serum levels of triglycerides were significantly elevated (58 and |
| 47%). However, all mean serum lipid and lipoprotein values remained within the normal range, and no change in the |
| calculated cholesterol ratio (HDL/total cholesterol) nor lipoprotein ratio (HDL/HDL + LDL) was observed. No |
| significant difference between the formulations could be detected with respect to the effect on serum lipids and |
| lipoproteins measured. The change in total cholesterol was smaller than reported in many studies of monophasic |
| preparations. Taken together, these data suggest that only small alterations in lipid metabolism are elicited by these |
| OCs. (PubHealth.info Document ID: CONT2T 4544-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "Effect of norethisterone and levonorgestrel in low-dose |
| multiphasic oral contraceptives on serum lipids.", is(are) Wiik P; Nordby J; Paulsen JE. The source of this article |
| is "Acta Obstetrica et Gynecologica Scandinavica. 1993 Oct;72(7):550-5.". This article was published in 1993 in |
| English language(s). (PubHealth.info® Document ID: CONT2T 4544-06. All rights reserved with PubHealth.info) PIN: |
| This article is peer-reviewed. |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |